A mixed-methods evaluation of adherence to preventive treatment among child tuberculosis contacts in Indonesia

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 8, 2016, Pages 1078-1083

  Triasih, Rina ^a,b   Padmawati, R S ^a   Duke, T ^b   Robertson, C ^c   Sawyer, S M ^b,d   Graham, S M ^b,e  

^a GADJAH MADA UNIVERSITY   (Indonesia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

Adherence; Child; Contact management; Preventive therapy; Tuberculosis

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL TRANSMISSION; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEALTH CARE ACCESS; HUMAN; INDONESIA; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOCIAL SUPPORT; TUBERCULOSIS; CAREGIVER; CLINICAL PRACTICE; CONTACT EXAMINATION; DRUG ADMINISTRATION; INFANT; INFORMATION PROCESSING; INTERVIEW; LUNG TUBERCULOSIS; NEWBORN; ODDS RATIO; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROTOCOL COMPLIANCE; RISK FACTOR; TIME FACTOR; TRANSMISSION; TREATMENT OUTCOME;

ANTITUBERCULAR AGENTS; CAREGIVERS; CHILD, PRESCHOOL; CONTACT TRACING; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOCUS GROUPS; GUIDELINE ADHERENCE; HUMANS; INDONESIA; INFANT; INFANT, NEWBORN; INTERVIEWS AS TOPIC; ISONIAZID; MALE; MEDICATION ADHERENCE; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY PREVENTION; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84978264496     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0952     Document Type: Article

References (31)

1. Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: A systematic review and metaanalysis. Eur Respir J2013; 41: 140-156.
2. Triasih R, Rutherford M, Lestari T, Utarini A, Robertson CF, Graham SM. Contact investigation of children exposed to tuberculosis in South East Asia: A systematic review. JTrop Med 2012; 2012: 301808.
3. Chiang SS, Khan FA,MilsteinMB, et al. Treatment outcomes of childhood tuberculous meningitis: A systematic review and meta-analysis. Lancet Infect Dis 2014; 14: 947-957.
4. Drobac PC, Shin SS, Huamani P, et al. Risk factors for inhospital mortality among children with tuberculosis: The 25- year experience in Peru. Pediatrics 2012; 130: E373-e379.
5. Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: A critical review of literature from the pre-chemotherapy era. Int JTuberc Lung Dis 2004; 8: 392-402.
6. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: A meta-analysis and assessment of costeffectiveness. Lancet 2006; 367: 1173-1180.
7. Ayieko J, Abuogi L, Simchowitz B, Bukusi EA, Smith AH, Reingold A. Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: A meta-analysis. BMC Infect Dis 2014; 14: 91.
8. Hsu KH. Thirty years after isoniazid. Its impact on tuberculosis in children and adolescents. JAMA 1984; 251: 1283-1285.
9. SmiejaMJ,Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000; (2): CD001363.
10. Hill PC, RutherfordME, Audas R, van Crevel R, Graham SM. Closing the policy-practice gap in the management of child contacts of tuberculosis cases in developing countries. PLOS MED 2011; 8: E1001105.
11. Rutherford ME, Hill PC, Triasih R, Sinfield R, van Crevel R, Graham SM. Preventive therapy in children exposed to Mycobacterium tuberculosis: Problems and solutions. Trop Med Int Health 2012; 17: 1264-1273.
12. Marais BJ, van Zyl S, Schaaf HS, van Aardt M, Gie RP, Beyers N. Adherence to isoniazid preventive chemotherapy: A prospective community based study. Arch Dis Child 2006; 91: 762-765.
13. Rutherford ME, Ruslami R, Maharani W, et al. Adherence to isoniazid preventive therapy in Indonesian children: A quantitative and qualitative investigation. BMC Res Notes 2012; 5: 7.
14. Triasih R, Robertson CF, Duke T, Graham SM. Aprospective evaluation of the symptom-based screening approach to the management of children who are contacts of tuberculosis cases. Clin Infect Dis 2015; 60: 12-18.
15. Garie KT, Yassin MA, Cuevas LE. Lack of adherence to isoniazid chemoprophylaxis in children in contact with adults with tuberculosis in Southern Ethiopia. PLOS ONE 2011; 6: E26452.
16. Gomes VF, Wejse C, Oliveira I, et al. Adherence to isoniazid preventive therapy in children exposed to tuberculosis: A prospective study from Guinea-Bissau. Int JTuberc Lung Dis 2011; 15: 1637-1643.
17. van Zyl S, Marais BJ, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. TInt JTuberc Lung Dis 2006; 10: 13-18.
18. Alperstein G, Morgan KR, Mills K, Daniels L. Compliance with anti-tuberculosis preventive therapy among 6-year-old children. Aust NZ JPublic Health 1998; 22: 210-213.
19. Machado A, Jr, Finkmoore B, Emodi K, et al. Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil. Int JTuberc Lung Dis 2009; 13: 719-725.
20. Donovan JL. Patient decision making. The missing ingredient in compliance research. Int JTechnol Assess Health Care 1995; 11: 443-455.
21. Griffith S. Areview of the factors associated with patient compliance and the taking of prescribed medicines. Br JGen Pract 1990; 40: 114-116.
22. Lassen LC. Patient compliance in general practice. Scand JPrim Health Care 1989; 7: 179-180.
23. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag 2008; 4: 269-286.
24. Lester R, Hamilton R, Charalambous S, et al. Barriers to implementation of isoniazid preventive therapy in HIV clinics: A qualitative study. AIDS 2010; 24 (Suppl 5): S45-S48.
25. Carey JW, Oxtoby MJ, Nguyen LP, Huynh V, Morgan M, Jeffery M. Tuberculosis beliefs among recent Vietnamese refugees in New York State. Public Health Rep 1997; 112: 66-72.
26. Cruz AT, Starke JR. Twice-weekly therapy for children with tuberculosis infection or exposure. Int JTuberc Lung Dis 2013; 17: 169-174.
27. Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998; 78: 169-171.
28. Sterling TR, VillarinoME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. NEngl JMed 2011; 365: 2155-2166.
29. Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: A meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009; 49: 1883-1889.
30. Hanifa Y, Mngadi K, Lewis J, Fielding K, Churchyard G, Grant AD. Evaluation of the Arkansas method of urine testing for isoniazid in South Africa. Int JTuberc Lung Dis 2007; 11: 1232-1236.
31. Perry S, HovellMF, Blumberg E, et al. Urine testing to monitor adherence to TB preventive therapy. JClin Epidemiol 2002; 55: 235-238.